Breast and cervical cancer in patients with systemic lupus erythematosus;Câncer cervical e de mama em pacientes com lúpus eritematoso sistêmico

Revista Brasileira de Ginecologia e Obstetricia

Volumn 36, Issue 8, 2014, Pages 367-371

  Skare, Thelma Larocca ^a,b   Da Rocha, Bruno Vinícius ^a,b  

^a HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^b Curso de Medicina   (Brazil)

Author keywords

Breast neoplasms complications; Cervix uteri pathology; Lupus erythematosus; Neoplasms; Systemic complications; Uterine cervical neoplasms complications

Indexed keywords

ADOLESCENT; ADULT; AGED; BRAZIL; BREAST NEOPLASMS; COMPLICATION; FEMALE; HUMAN; INCIDENCE; MIDDLE AGED; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84906882619     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: 10.1590/SO100-720320140005052     Document Type: Article

References (25)

1. Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin North Am. 2013;57(4):631-55.
2. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum. 1991;21(1):55-64.
3. Merrell M, Shulman LE. Determination of prognosis in chronic disease illustrated by systemic lupus erythematosus. J Chronic Dis. 1955;1(1):12-32.
4. Bernatsky S, Kale M, Ramsey-Goldman R, Gordon C, Clarke AE. Systemic lupus and malignancies. Curr Opin Rheumatol. 2012;24(2):177-81.
5. Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term follow up study in a Danish cohort. Arthritis Rheum. 2011;63(10):3032-7.
6. Hellstrom KE, Hellstrom I. Vaccines to treat cancer-an old approach whose time has arrived. J Cell Biochem. 2007;102(2):291-300.
7. Feng Q, Wei H, Morihara J, Stern J, Yu M, Kiviat N, et al. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol. 2012;127(2):412-9.
8. Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer. 2011;104(9):1478-81.
9. Dema B, Charles N. Advances in mechanisms of systemic lupus erythematosus. Discov Med. 2014;17(95):247-55.
10. de Souza VS, Santos RV. The emergence of human population genetics and narratives about the formation of the Brazilian nation (1950-1960). Stud Hist Philos Biol Biomed Sci. 2014 [ahead of print].
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
12. Brasil. Ministério da Saúde. Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) [Internet]. Estimativa 2014: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2014 [citado 2014 Abr 14]. Disponível em:
13. Klumb EM, Pinto AC, Jesus GR, Araujo M Jr, Jascone L, Gayer CR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19(13):1485-91.
14. Padula SJ, Clark RB, Korn JH. Cell-mediated immunity in rheumatic disease. Hum Pathol. 1986;17(3):254-63.
15. Garred P, Voss A, Madsen HO, Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun. 2001;2(8):442-50.
16. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013;36(6):393-412.
17. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659-64.
18. Soybilgic A, Onel KB, Utset T, Alexander K, Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatric Rheumatol Online J [Internet]. 2013 [cited 2014 Jan 25];11:29. Available from:
19. Liu HW, Lin HL, Yen JH, Tsai WC, Chiou SS, Chang JG, et al. Demethylation within the proximal promoter region of human estrogen receptor alpha gene correlates with its enhanced expression: implications for female bias in lupus. Mol Immunol. 2014;61(1):28-37.
20. Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, et al. Breast cancer in systemic lupus erythematosus. Oncology. 2013;85(2):117-21.
21. Colditz GA, Bohlke K, Berkey CS. Breast cancer risk accumulation starts early: prevention must also. Breast Cancer Res Treat. 2014;145(3):567-79.
22. Cecil DL, Park KH, Gad E, Childs JS, Higgins DM, Plymate SR, et al. T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity. Breast Cancer Res Treat. 2013;139(3):657-65.
23. Sinicato NA, Postal M, Peres FA, Peliçari KO, Marini R, dos Santos AO, et al. Obesity and cytokines in childhood-onset systemic lupus erythematosus. J Immunol Res. 2014;2014:162047.
24. Bidgoli SA, Azarshab H. Role of vitamin D deficiency and lack of sun exposure in the incidence of premenopausal breast cancer: a case control study in Sabzevar, Iran. Asian Pac J Cancer Prev. 2014;15(8):3391-6.
25. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342-57.